NEWS | September 25, 2018

Sutcliffe elected 2020 president of World Molecular Imaging Society


Julie Sutcliffe, UC Davis professor of Internal Medicine and Biomedical Engineering and a member of the UC Davis Comprehensive Cancer Center, has been named the 2020 president-elect of the World Molecular Imaging Society (WMIS).

Julie Sutcliffe Julie Sutcliffe

“It’s an honor to be considered for the position of WMIS president, and I’m excited to work with all stakeholders to advance our field,” Sutcliffe said.

Sutcliffe formally accepted the role during the WMIS annual meeting Sept. 12-15 in Seattle, Wash. Her one-year term as president will officially begin in September 2019.

“We are so very proud of Julie and her many accomplishments, including this latest international honor,” said UC Davis Biomedical Engineering Department Chair Alyssa Panitch. “Anyone who knows Julie knows her true passion for patient care, and I’m absolutely thrilled that she’ll be bringing that passion to her new role at WMIS.”

Sutcliffe’s presidential priorities include:
· Strengthening alliances between industry and academia to enable rapid translation of discoveries from the laboratory to the clinic
· Improving education across sub-disciplines to help prepare for the future of molecular imaging
· Engaging patients and advocates to help molecular imaging scientists understand important clinical challenges and concerns

“We are the community who reaches across disciplines, working together to design and build new tools that reveal the molecular basis of disease,” Sutcliffe said. “In my role as WMIS president, I will focus efforts on advancing the field of molecular imaging to the benefit of all.”

Sutcliffe’s work in the field enabled development of target-specific molecular imaging agents, which have been approved by the FDA for investigational use and are being used successfully in the clinical setting at UC Davis Medical Center. Her work has the potential to impact early disease detection and subsequent treatment for patients with pancreatic cancer.